The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...

KEGE Center for ADHD, a psychiatric practice dedicated to evidence-based ADHD care, has expanded and enhanced its core services to better serve patients across Arizona. These improvements aim to ...

Dr. Ajoke Akintade, a neurodevelopmental pediatrician and interim chief medical officer at Mt. Washington Pediatric Hospital, ...

While our immune systems typically do a great job containing pathogens and clearing infections, they can occasionally ...

As a business leader in Louisiana, I can’t stress enough about the importance of ensuring affordability. People are leaving ...

In today's Asking Eric column, R. Eric Thomas shares a reader's advice about how to support those who have been diagnosed ...

Startup Leo Cancer Care is transforming proton radiation treatment with a simple idea: having patients sit up instead of ...

UCSF Health is advancing a new chapter in its commitment to San Francisco by strengthening two long-standing community hospitals through targeted investments in facilities, technology, and operations ...

October marks Attention-Deficit/Hyperactivity Disorder (ADHD) awareness month and the focus this year is on the many faces of ...

ADHD may not be overdiagnosed at all. Researchers say it’s more accurate to view it as a spectrum condition that changes over ...

Many news outlets have reported an increase—or surge—in attention-deficit/hyperactivity disorder, or ADHD, diagnoses in both ...

CTx-1301 is a novel proprietary formulation of dexmethylphenidate, a stimulant that increases norepinephrine and dopamine activity in the brain.